Market Overview:
The global ischemic stroke therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of ischemic stroke, rising geriatric population, and technological advancements in the field of stroke therapeutics. Based on type, the global ischemic stroke therapeutics market can be segmented into tissue plasminogen activator (tPA), anticoagulant, antiplatelet, and antihypertensive drugs. tPA dominates this market due to its high efficacy in dissolving blood clots that cause strokes. Based on application, hospitals account for the majority share of this market followed by clinics and ambulatory surgical centers (ASCs). Geographically, North America dominates the global ischemic stroke therapeutics market followed by Europe and Asia Pacific.
Product Definition:
Ischemic stroke therapeutics is a term used to describe the various treatments available for ischemic stroke. These treatments are aimed at restoring blood flow to the brain and preventing further damage. The importance of ischemic stroke therapeutics cannot be overstated, as this condition accounts for 87% of all strokes and can lead to serious disability or death.
Tissue Plasminogen Activator:
Tissue Plasminogen Activator is a blood clot dissolving drug that works by promoting the process of fibrinolysis. It helps in increasing the amount of plasminogen activators in the blood, which enables it to dissolve clots more efficiently. Tissue plasminogen activator is used for treating patients who have suffered a stroke and are at risk of developing another one.
Anticoagulant:
Anticoagulant is a drug that reduces the coagulation of blood. It works by interference with the normal clotting mechanism and hence prevents or delays blood from clotting. Anticoagulants are used in medical treatment for patients suffering from diseases such as deep vein thrombosis, pulmonary embolism, renal dialysis, and cancer among others.
Application Insights:
Based on application, the global ischemic stroke therapeutics market is segmented into hospitals, clinics, ambulatory surgical centers and others. Hospitals held the largest share in 2017 owing to factors such as availability of advanced healthcare facilities and highly skilled medical staffs. Moreover, government initiatives such as National ICT Heart Foundation (NICTHF)¢â‚¬â„¢s National Stroke Program and American Heart Association (AHA) make it easy for patients suffering from a stroke at any age to access treatment at hospitals. As per AHA guidelines published in 2016, every hospital should be offering a dedicated Stroke Service where all necessary diagnostic tests are carried out and appropriate treatment started within 3 days of admission.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing geriatric population, prevalence of hypertension, and smoking prevalence. Moreover, favorable reimbursement policies for various treatment options are also driving growth in this region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising healthcare expenditure by governments and private sectors as well as improving healthcare infrastructure in emerging countries such as China and India. Growing target disease population base along with increasing incidence of stroke will drive regional market growth during the estimated time span. Furthermore, growing medical tourism industry will further boost demand for these products leading to an increase in revenue generation capacity within Asia Pacific economies over next few years (Hospitals & Clinics 2018; Blood Pressure Control 2018).
Growth Factors:
- Increasing incidence of ischemic stroke
- Growing geriatric population
- Rising prevalence of lifestyle diseases such as obesity and diabetes mellitus
- Technological advancements in the field of ischemic stroke therapeutics
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Ischemic Stroke Therapeutics Market Research Report
By Type
Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, Antihypertensive, Others
By Application
Hospitals, Clinics, Ambulatory Surgical Centers, Others
By Companies
Pfizer, Merck, Boehringer Ingelheim, Sanofi, Johnson & Johnson, Bayer, Biogen, Abbott Laboratories, Genentech, Daiichi Sankyo
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
189
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Ischemic Stroke Therapeutics Market Report Segments:
The global Ischemic Stroke Therapeutics market is segmented on the basis of:
Types
Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, Antihypertensive, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Ambulatory Surgical Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Merck
- Boehringer Ingelheim
- Sanofi
- Johnson & Johnson
- Bayer
- Biogen
- Abbott Laboratories
- Genentech
- Daiichi Sankyo
Highlights of The Ischemic Stroke Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- Others
- By Application:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ischemic Stroke Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ischemic stroke therapies are medications or treatments that help to improve the symptoms of ischemic stroke. These therapies can include medications to reduce the amount of blood clotting in the brain, treatments to improve blood flow to the brain, and devices that help increase blood flow to the brain.
Some of the major companies in the ischemic stroke therapeutics market are Pfizer, Merck, Boehringer Ingelheim, Sanofi, Johnson & Johnson, Bayer, Biogen, Abbott Laboratories, Genentech, Daiichi Sankyo.
The ischemic stroke therapeutics market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ischemic Stroke Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ischemic Stroke Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ischemic Stroke Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ischemic Stroke Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ischemic Stroke Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Ischemic Stroke Therapeutics Market Size and Y-o-Y Growth
4.5.2 Ischemic Stroke Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Ischemic Stroke Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Ischemic Stroke Therapeutics Market Size Forecast by Type
5.2.1 Tissue Plasminogen Activator
5.2.2 Anticoagulant
5.2.3 Antiplatelet
5.2.4 Antihypertensive
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Ischemic Stroke Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Ischemic Stroke Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Ambulatory Surgical Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ischemic Stroke Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ischemic Stroke Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Ischemic Stroke Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Ischemic Stroke Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Ischemic Stroke Therapeutics Market Size Forecast by Type
9.6.1 Tissue Plasminogen Activator
9.6.2 Anticoagulant
9.6.3 Antiplatelet
9.6.4 Antihypertensive
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Ischemic Stroke Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Ambulatory Surgical Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Ischemic Stroke Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Ischemic Stroke Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Ischemic Stroke Therapeutics Market Size Forecast by Type
10.6.1 Tissue Plasminogen Activator
10.6.2 Anticoagulant
10.6.3 Antiplatelet
10.6.4 Antihypertensive
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Ischemic Stroke Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Ambulatory Surgical Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Ischemic Stroke Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Ischemic Stroke Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Ischemic Stroke Therapeutics Market Size Forecast by Type
11.6.1 Tissue Plasminogen Activator
11.6.2 Anticoagulant
11.6.3 Antiplatelet
11.6.4 Antihypertensive
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Ischemic Stroke Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Ambulatory Surgical Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Ischemic Stroke Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Ischemic Stroke Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Ischemic Stroke Therapeutics Market Size Forecast by Type
12.6.1 Tissue Plasminogen Activator
12.6.2 Anticoagulant
12.6.3 Antiplatelet
12.6.4 Antihypertensive
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Ischemic Stroke Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Ambulatory Surgical Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Ischemic Stroke Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Ischemic Stroke Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Ischemic Stroke Therapeutics Market Size Forecast by Type
13.6.1 Tissue Plasminogen Activator
13.6.2 Anticoagulant
13.6.3 Antiplatelet
13.6.4 Antihypertensive
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Ischemic Stroke Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Ambulatory Surgical Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ischemic Stroke Therapeutics Market: Competitive Dashboard
14.2 Global Ischemic Stroke Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Merck
14.3.3 Boehringer Ingelheim
14.3.4 Sanofi
14.3.5 Johnson & Johnson
14.3.6 Bayer
14.3.7 Biogen
14.3.8 Abbott Laboratories
14.3.9 Genentech
14.3.10 Daiichi Sankyo
